🔥🐔 BizChicken 🐔🔥
Companies Similar to Cabaletta Bio, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
BioAtla, Inc.
BA3011
Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.
Symbol: BCAB
Recent Price: $0.59
Industry: Biotechnology
CEO: Dr. Jay M. Short Ph.D.
Sector: Healthcare
Employees: 65
Address: 11085 Torreyana Road, San Diego, CA 92121
Phone: 858 558 0708
Last updated: 2024-12-31
CARGO Therapeutics, Inc. Common Stock
CRG-022
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.
About | Leadership | Directors | About | Contact | Contact | Careers | Careers | Careers | Careers | About | About
Symbol: CRGX
Recent Price: $13.76
Industry: Biotechnology
CEO: Ms. Gina Chapman
Sector: Healthcare
Employees: 150
Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403
Phone: 650-379-6143
Leadership
- Gina Chapman, President and Chief Executive Officer
- Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
- Ginna Laport, MD, Chief Medical Officer
- Shishir Gadam, PhD, Chief Technical Officer
- Michael Ports, PhD, Chief Scientific Officer
- Kari Leetch, Chief People Officer
- Halley Gilbert, JD, Chief Legal Officer
- Bethany Rogers, SVP, Product Strategy and Commercialization
- Faisal Shawwa, SVP, Finance
- Tonia J. Buchholz, PhD, Head of Clinical Science
- Kanika Chawla, PhD, Head of Process Sciences
- Sandra Chen, Head of Clinical Quality and Risk Management
- Michelle Gray, Head of Clinical Operations
- Adam Haskett, Head of External Manufacturing
- David Hoffman, JD, Head of Intellectual Property & Transactions
- Anissa Irwin, Head of Quality Assurance and Systems
- Brett Masterson, Head of Marketing
- Rob McCombie, Head of CMC Regulatory
- Frank McDonald, Head of Clinical Data Management
- Priya Parameswaran, Head of Corporate Strategy and Business Operations
- Shabnum Patel, PHD, Head of MSAT
- Mary Rodley, Head of CMC Strategy and Operations
- Abhijeet Sarvaiya, Head of Statistical Programming
- Brian Schoelkopf, Head of FP&A
- Christophe Suchet, Head of IT
- Beth Vasievich, PhD, Head of Commercial Planning and Operations
- Jun Wang, Head of Procurement
- John Orwin, Chairman of the Board
- Abraham Bassan, Board Director
- Kapil Dhingra, M.B.B.S, Board Director
- Reid Huber, PHD, Board Director
- David Lubner, Board Director
- Krishnan Viswanadhan, Pharm.D, Board Director
- Jane Pritchett Henderson, Board Director
Last updated: 2024-12-31
PharmaCyte Biotech, Inc.
Cell-in-a-Box
Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.
About | Management | Directors | ESG | About | Directors | Contact | ESG | About | About | About | About
Symbol: PMCB
Recent Price: $1.55
Industry: Biotechnology
CEO: Mr. Joshua N. Silverman
Sector: Healthcare
Employees: 2
Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169
Phone: 917 595 2850
Leadership
- Joshua N. Silverman, Independent Director
- Dr. Michael M. Abecassis, Independent Director
- Robert Weinstein, Director
- Wayne R. Walker, Director
- Jonathan L. Schechter, Independent Director
- Dr. Abecassis, Director
- Kenneth L. Waggoner, Independent Director
- Daniel C. Farb, Independent Director
- Daniel C. Allen, Independent Director
- Jack E. Stover, Independent Director
Last updated: 2024-12-31
Adicet Bio, Inc.
ADI-001
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.
Symbol: ACET
Recent Price: $0.90
Industry: Biotechnology
CEO: Mr. Chen Schor BA, CPA, M.B.A.
Sector: Healthcare
Employees: 143
Address: 200 Clarendon Street, Boston, MA 02116
Phone: 650 503 9095
Last updated: 2024-12-31
Arcellx, Inc.
CART-dd BCMA
Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.
About | About | News | Contact | Contact | Culture | Culture | Culture | Culture | About | About | About | About | About | News
Symbol: ACLX
Recent Price: $78.35
Industry: Biotechnology
CEO: Mr. Rami Elghandour
Sector: Healthcare
Employees: 130
Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878
Phone: 240 327 0603
Last updated: 2024-12-31
Agenus Inc.
Retrocyte Display
Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.
Symbol: AGEN
Recent Price: $2.69
Industry: Biotechnology
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Employees: 389
Address: 3 Forbes Road, Lexington, MA 02421-7305
Phone: 781 674 4400
Last updated: 2024-12-31
Allogene Therapeutics, Inc.
UCART19
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
About | About | About | Contact | Contact | Careers | Careers | Jobs | About | About | About | About | About | About
Symbol: ALLO
Recent Price: $2.10
Industry: Biotechnology
CEO: Dr. David D. Chang M.D., Ph.D.
Sector: Healthcare
Employees: 232
Address: 210 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 457 2700
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Cabaletta Bio, Inc.
DSG3-CAART
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.
Symbol: CABA
Recent Price: $2.24
Industry: Biotechnology
CEO: Dr. Steven A. Nichtberger M.D.
Sector: Healthcare
Employees: 136
Address: 2929 Arch Street, Philadelphia, PA 19104
Phone: 267 759 3100
Leadership
- Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
- Samik Basu, M.D., Chief Scientific Officer
- Gwendolyn Binder, Ph.D., President, Science & Technology
- David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
- Arun Das, M.D., Chief Business Officer
- Michael Gerard, General Counsel
- Heather Harte-Hall, Chief Compliance Officer
- Anup Marda, Chief Financial Officer
- Martha O’Connor, Chief Human Resources Officer
- Sarah Yuan, Ph.D., Chief Technology Officer
- Catherine Bollard, M.D., Independent Director, George Washington University
- Scott Brun, M.D., Independent Director, formerly at AbbVie
- Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
- Mark Simon, M.B.A., Independent Director, Torreya Partners
- Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Caribou Biosciences, Inc.
CB-010, CB-011, CB-012, CB-020
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.
About | About | Contact | Contact | Careers | Jobs | Benefits | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Careers | About | About | Vision/Values | DEI | Benefits
Symbol: CRBU
Recent Price: $1.61
Industry: Biotechnology
CEO: Dr. Rachel E. Haurwitz Ph.D.
Sector: Healthcare
Employees: 158
Address: 2929 7th Street, Berkeley, CA 94710
Phone: 510 982 6030
Last updated: 2024-12-31
Gossamer Bio, Inc.
GB002, GB004, GB5121, GB7208
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.
About | About | Management | Directors | Contact | Locations | Contact | Contact | About | About
Symbol: GOSS
Recent Price: $0.88
Industry: Biotechnology
CEO: Mr. Faheem Hasnain
Sector: Healthcare
Employees: 135
Address: 3013 Science Park Road, San Diego, CA 92121
Phone: 858 684 1300
Leadership
- Faheem Hasnain, Chairman
- Richard Aranda, M.D., Chief Medical Officer
- Jeff Boerneke, General Counsel and Secretary
- Matt Cravets, Senior Vice President, Biometrics
- Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
- Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
- Caryn Peterson, Executive Vice President, Regulatory Affairs
- Bob Smith, Chief Commercial Officer
- Christian Waage, Executive Vice President, Technical Operations & Administration
- Deanna Weber, Senior Vice President, Human Resources
- Russell J. Cox, Director
- Thomas Daniel, Director
- Skye Drynan, Director
- Sandra Milligan, Director
- Steven D. Nathan, Director
- John Quisel, Director
Last updated: 2024-12-31
Palisade Bio, Inc.
LB1148
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral therapies targeting serious diseases related to the breakdown of the gastrointestinal mucosal barrier. Their lead product, LB1148, is designed to protect gut integrity during intestinal stress.
Symbol: PALI
Recent Price: $1.70
Industry: Biotechnology
CEO: Mr. J. D. Finley
Sector: Healthcare
Employees: 9
Address: 5800 Armada Drive, Carlsbad, CA 92008
Phone: 858 704 4900
Last updated: 2024-12-31
PDS Biotechnology Corporation
PDS0101
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.
Symbol: PDSB
Recent Price: $1.69
Industry: Biotechnology
CEO: Dr. Frank K. Bedu-Addo Ph.D.
Sector: Healthcare
Employees: 25
Address: 25B Vreeland Road, Florham Park, NJ 07932
Phone: 800 208 3343
Leadership
- Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
- Stephan Toutain, Chief Operating Officer
- Lars Boesgaard, Chief Financial Officer
- Gregory Conn, Ph.D., Chief Scientific Officer
- Kirk Shepard, M.D., Chief Medical Officer
- Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
- Rory Cullinane, Vice President of Quality
- Joe Dervan, Ph.D., Vice President of Research and Development
- David Schaaf, M.D., Vice President of Medical Affairs
- Sir Richard Sykes, Director
- Ilian Iliev, Ph.D., Director
- Gregory Freitag, J.D., CPA, Director
- Otis W. Brawley, M.D., Director
- Kamil Ali-Jackson, J.D., Director
- Stephen Glover, Chairman
Last updated: 2024-12-31
SAB Biotherapeutics, Inc.
SAB-185, SAB-176
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focusing on developing immunotherapies based on human antibodies, using advanced genetic engineering to produce fully-human polyclonal antibodies targeting diseases such as COVID-19, influenza, autoimmune disorders, and cancer.
Symbol: SABS
Recent Price: $4.15
Industry: Biotechnology
CEO: Mr. Samuel J. Reich
Sector: Healthcare
Employees: 57
Address: 2100 East 54th Street North, Sioux Falls, SD 57104
Phone: 605 679 6980
Last updated: 2024-12-31
Solid Biosciences Inc.
SGT-001
Solid Biosciences Inc. focuses on developing therapies for Duchenne muscular dystrophy, with lead product candidates like SGT-001 and SGT-003, and platform technologies like dual gene expression. The company is headquartered in Cambridge, Massachusetts, and collaborates with Ultragenyx Pharmaceutical Inc.
Vision/Values | Vision/Values | Vision/Values | About | Management | Directors | About | About | About | Culture | Benefits | About | Culture | Vision/Values | Contact | Contact | About | About
Symbol: SLDB
Recent Price: $4.07
Industry: Biotechnology
CEO: Mr. Alexander G. Cumbo
Sector: Healthcare
Employees: 88
Address: 141 Portland Street, Cambridge, MA 02139
Phone: 617 337 4680
Leadership
- Ian F. Smith, Chairman of the Board
- Bo Cumbo, President and CEO
- Martin Freed, M.D., F.A.C.P., Board Member
- Ilan Ganot, Co-Founder and Strategic Advisor to the CEO
- Clare Kahn, Ph.D., Board Member
- Georgia Keresty, Ph.D., M.PH., Board Member
- Sukumar Nagendran, M.D., President, Head of Research & Development, Taysha Gene Therapies
- Adam Stone, Chief Investment Officer of Perceptive Advisors
- Lynne Sullivan, Chief Financial Officer at Unity Biotechnology
Last updated: 2024-12-31
2seventy bio, Inc.
idecabtagene vicleucel
2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.
Symbol: TSVT
Recent Price: $2.89
Industry: Biotechnology
CEO: Mr. William D. Baird III, M.B.A.
Sector: Healthcare
Employees: 274
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Galecto, Inc.
GB2064
Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.
Symbol: GLTO
Recent Price: $4.60
Industry: Biotechnology
CEO: Dr. Hans T. Schambye M.D., Ph.D.
Sector: Healthcare
Employees: 13
Address: 75 State Street, Boston, MA 02109
Phone: 457 070 5210
Last updated: 2024-12-31